Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: Results of a phase 1 trial

Journal of Clinical Pharmacology

Volumn 51, Issue 12, 2011, Pages 1674-1684

  Awada, Ahmad ^a   Gil, Thierry ^a   Whenham, Nicolas ^a   Van Hamme, Julie ^a   Besse Hammer, Tatiana ^a   Brendel, Erich ^b   Delesen, Heinz ^b   Joosten, Miranda C ^c   Lathia, Chetan D ^d   Loembé, Bienvenu A ^c   Piccart Ghebart, Martine ^a   Hendlisz, Alain ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b BAYER PHARMA AG   (Germany)

^c Bayer BV   (Netherlands)

^d BAYER CORPORATION   (United States)

Author keywords

Capecitabine; combination; phase 1; solid tumors; sorafenib

Indexed keywords

CAPECITABINE; FLUOROURACIL; SORAFENIB;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CLINICAL ARTICLE; COLORECTAL CANCER; COUGHING; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; KIDNEY CARCINOMA; MALE; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; PANCREAS CANCER; PATIENT COMPLIANCE; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; SENSORY NEUROPATHY; SOLID TUMOR; STOMATITIS; TREATMENT REFUSAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BENZENESULFONATES; COLONIC NEOPLASMS; DEOXYCYTIDINE; DIARRHEA; FATIGUE; FEMALE; FLUOROURACIL; HAND-FOOT SYNDROME; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIDINES;

EID: 80051564889     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010386226     Document Type: Article

References (39)

1. Levy JB, Pauloski N, Braun D, et al. Analysis of transcription and protein expression changes in the 786-O human renal cell carcinoma tumor xenograft model in response to treatment with the multi-kinase inhibitor sorafenib (BAY 43-9006). Proc Am Assoc Cancer Res. 2006 ; 47: 213-214
2. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004 ; 64: 7099-7109 (Pubitemid 39331023)
3. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006 ; 24: 2505-2512 (Pubitemid 46630627)
4. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007 ; 356: 125-134 (Pubitemid 46089673)
5. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009 ; 27: 3312-3318
6. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 ; 359: 378-390
7. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 ; 10: 25-34
8. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006 ; 24: 4293-4300 (Pubitemid 46630787)
9. Flaherty KT, Brose M, Schuchter LM, et al. Sorafenib combined with carboplatin and paclitaxel for metastatic melanoma: progression-free survival and response versus B-RAF status. Ann Oncol. 2006 ; 17: iii33
10. Eisen T, Ahmad T, Gore ME, et al. Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients. J Clin Oncol. 2005 ; 23 :
11. Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer. 2006 ; 95: 581-586 (Pubitemid 44325897)
12. Gatzemeier U, Blumenschein G, Fosella F, et al. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. J Clin Oncol. 2006 ; 24: 364s
13. Richly H, Henning BF, Kupsch P, et al. Results of a phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol. 2006 ; 17: 866-873
14. Schiller JH, Flaherty KT, Redlinger M, et al. Sorafenib combined with carboplatin/paclitaxel for advanced non-small cell lung cancer: a phase I subset analysis. J Clin Oncol. 2006 ;: 24
15. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006 ; 5: 835-844 (Pubitemid 44480537)
16. Baselga J, Segalla JGM, Roché H, et al. 3LBA SOLTI-0701: a double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib (SOR) compared to placebo (PL) when administered in combination with capecitabine (CAP) in patients (pts) with locally advanced (adv) or metastatic (met) breast cancer (BC). Eur J Cancer Suppl. 2009 ; 7: 3-4
17. Gollob JA, Wilhelm S, Carter C, Kelley SL. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol. 2006 ; 33: 392-406 (Pubitemid 44142735)
18. Figer A, Moscovici M, Bulocinic S, et al. Phase I trial of BAY 43-9006 in combination with 5-fluorouracil (5-FU) and leucovorin (LCV) in patients with advanced refractory solid tumors. Ann Oncol. 2004 ; 15: iii87
19. Kupsch P, Henning BF, Passarge K, et al. Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin Colorectal Cancer. 2005 ; 5: 188-196
20. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 1989 ; 16: 215-237 (Pubitemid 19114713)
21. Kufe DW, Major PP. 5-fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity. J Biol Chem. 1981 ; 256: 9802-9805 (Pubitemid 12176177)
22. Ershler WB. Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer. Oncologist. 2006 ; 11: 325-335
23. Natarajan N, Shuster TD. New agents, combinations, and opportunities in the treatment of advanced and early-stage colon cancer. Surg Clin North Am. 2006 ; 86: 1023-1043 (Pubitemid 44192591)
24. Yu C, Bruzek LM, Meng XW, et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene. 2005 ; 24: 6861-6869 (Pubitemid 41509409)
25. Montville, NJ: Bayer HealthCare Pharmaceuticals Inc ; 2009 :
26. San Francisco, Calif: Genentech Inc ; 2009 :
27. Hotte SJ, Hirte HW. BAY 43-9006: early clinical data in patients with advanced solid malignancies. Curr Pharm Des. 2002 ; 8: 2249-2253 (Pubitemid 35189897)
28. Lathia C, Lettieri J, Cihon F, et al. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol. 2006 ; 57: 685-692
29. Guichard SM, Mayer I, Jodrell DI. Simultaneous determination of capecitabine and its metabolites by HPLC and mass spectrometry for preclinical and clinical studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 ; 826: 232-237 (Pubitemid 41446455)
30. Gressett SM, Stanford BL, Hardwicke F. Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract. 2006 ; 12: 131-141 (Pubitemid 44696441)
31. Nagore E, Insa A, Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ("hand-foot") syndrome: incidence, recognition and management. Am J Clin Dermatol. 2000 ; 1: 225-234
32. Robert C, Mateus C, Spatz A, et al. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol. 2009 ; 60: 299-305
33. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol. 2005 ; 23: 965-972 (Pubitemid 46202316)
34. O'Neill VJ, Cassidy J. Capecitabine in the treatment of colorectal cancer. Future Oncol. 2005 ; 1: 183-190
35. Walko CM, Lindley C. Capecitabine: a review. Clin Ther. 2005 ; 27: 23-44 (Pubitemid 40347299)
36. Escudier B, Lassau N, Angevin E, et al. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res. 2007 ; 13: 1801-1809 (Pubitemid 46952949)
37. Siu LL, Awada A, Takimoto CH, et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res. 2006 ; 12: 144-151 (Pubitemid 43166188)
38. Mross K, Steinbild S, Baas F, et al. Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. Eur J Cancer. 2007 ; 43: 55-63 (Pubitemid 46054474)
39. Awada A, Hendlisz A, Gil T, et al. A phase I study of BAY 43-9006, a novel Raf kinase and VEGFR inhibitor, in combination with taxotere in patients with advanced solid tumors. Eur J Cancer Suppl. 2004 ; 2: 114